Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
Updated results of the CLL8 trial confirm that the addition of rituximab to chemotherapy with fludarabine and cyclophosphamide (FC) leads to a prolongation of progression-free (PFS) and overall survival (OS) in first-line treatment of physically fit patients. After a median observation time of 47 mo...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
12 Jun 2013
|
| In: |
Leukemia and lymphoma
Year: 2013, Jahrgang: 54, Heft: 8, Pages: 1821-1822 |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428194.2013.796050 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3109/10428194.2013.796050
|
| Verfasserangaben: | Paula Cramer, Anna-Maria Fink, Raymonde Busch, Barbara Eichhorst, Clemens-Martin Wendtner, Natali Pflug, Petra Langerbeins, Jasmin Bahlo, Valentin Goede, Friederike Schubert, Hartmut Döhner, Stephan Stilgenbauer, Peter Dreger, Michael Kneba, Sebastian Böttcher, Jiri Mayer, Michael Hallek and Kirsten Fischer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1759085642 | ||
| 003 | DE-627 | ||
| 005 | 20220819215829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210527s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10428194.2013.796050 |2 doi | |
| 035 | |a (DE-627)1759085642 | ||
| 035 | |a (DE-599)KXP1759085642 | ||
| 035 | |a (OCoLC)1341414713 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cramer, Paula |d 1981- |e VerfasserIn |0 (DE-588)1011246384 |0 (DE-627)658059556 |0 (DE-576)341185671 |4 aut | |
| 245 | 1 | 0 | |a Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group |c Paula Cramer, Anna-Maria Fink, Raymonde Busch, Barbara Eichhorst, Clemens-Martin Wendtner, Natali Pflug, Petra Langerbeins, Jasmin Bahlo, Valentin Goede, Friederike Schubert, Hartmut Döhner, Stephan Stilgenbauer, Peter Dreger, Michael Kneba, Sebastian Böttcher, Jiri Mayer, Michael Hallek and Kirsten Fischer |
| 264 | 1 | |c 12 Jun 2013 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.05.2021 | ||
| 520 | |a Updated results of the CLL8 trial confirm that the addition of rituximab to chemotherapy with fludarabine and cyclophosphamide (FC) leads to a prolongation of progression-free (PFS) and overall survival (OS) in first-line treatment of physically fit patients. After a median observation time of 47 months, median PFS was 57.9 months for patients treated with FC and rituximab (FCR) and 32.9 months for patients treated with FC alone (hazard ratio 0.56, 95% confidence interval 0.465-0.673; p < 0.001). A total of 232 patients were treated for relapse, among them 91 of 408 (22%) initially treated with FCR and 141 of 409 (35%) initially treated with FC. The drugs most frequently used either alone or in combination were rituximab (52% of all second-line therapies), fludarabine (21%), bendamustine (21%) and alemtuzumab (12%). The regimens chosen for second-line treatment after FC or FCR were heterogeneous, which underlines a need for further trials in order to define treatment recommendations for patients with relapsed chronic lymphocytic leukemia. | ||
| 700 | 1 | |a Fink, Anna-Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Busch, Raymonde |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eichhorst, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wendtner, Clemens-Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pflug, Natali |e VerfasserIn |4 aut | |
| 700 | 1 | |a Langerbeins, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bahlo, Jasmin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goede, Valentin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schubert, Friederike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Döhner, Hartmut |d 1957- |e VerfasserIn |0 (DE-588)110666585 |0 (DE-627)729880842 |0 (DE-576)375358846 |4 aut | |
| 700 | 1 | |a Stilgenbauer, Stephan |d 1966- |e VerfasserIn |0 (DE-588)114728380 |0 (DE-627)590333151 |0 (DE-576)302364781 |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Kneba, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Böttcher, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayer, Jiri |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hallek, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fischer, Kirsten |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 54(2013), 8, Seite 1821-1822 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group |
| 773 | 1 | 8 | |g volume:54 |g year:2013 |g number:8 |g pages:1821-1822 |g extent:12 |a Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group |
| 856 | 4 | 0 | |u https://doi.org/10.3109/10428194.2013.796050 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210527 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 999 | |a KXP-PPN1759085642 |e 3931866661 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupLeukemia and lymphoma","note":["Gesehen am 08.09.15"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Leukemia and lymphoma","title":"Leukemia and lymphoma"}],"language":["eng"],"origin":[{"dateIssuedDisp":"1989-","publisher":"Taylor & Francis Group ; Informa Healthcare","publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989"}],"recId":"324746237","id":{"zdb":["2030637-4"],"issn":["1029-2403"],"eki":["324746237"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1989/90 -"],"part":{"extent":"12","year":"2013","volume":"54","text":"54(2013), 8, Seite 1821-1822","pages":"1821-1822","issue":"8"}}],"title":[{"title_sort":"Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group","title":"Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group"}],"id":{"doi":["10.3109/10428194.2013.796050"],"eki":["1759085642"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"12 S."}],"person":[{"role":"aut","display":"Cramer, Paula","given":"Paula","family":"Cramer"},{"family":"Fink","given":"Anna-Maria","display":"Fink, Anna-Maria","role":"aut"},{"display":"Busch, Raymonde","role":"aut","family":"Busch","given":"Raymonde"},{"given":"Barbara","family":"Eichhorst","role":"aut","display":"Eichhorst, Barbara"},{"role":"aut","display":"Wendtner, Clemens-Martin","given":"Clemens-Martin","family":"Wendtner"},{"display":"Pflug, Natali","role":"aut","family":"Pflug","given":"Natali"},{"given":"Petra","family":"Langerbeins","role":"aut","display":"Langerbeins, Petra"},{"family":"Bahlo","given":"Jasmin","display":"Bahlo, Jasmin","role":"aut"},{"given":"Valentin","family":"Goede","role":"aut","display":"Goede, Valentin"},{"role":"aut","display":"Schubert, Friederike","given":"Friederike","family":"Schubert"},{"family":"Döhner","given":"Hartmut","display":"Döhner, Hartmut","role":"aut"},{"display":"Stilgenbauer, Stephan","role":"aut","family":"Stilgenbauer","given":"Stephan"},{"given":"Peter","family":"Dreger","role":"aut","display":"Dreger, Peter"},{"given":"Michael","family":"Kneba","role":"aut","display":"Kneba, Michael"},{"given":"Sebastian","family":"Böttcher","role":"aut","display":"Böttcher, Sebastian"},{"display":"Mayer, Jiri","role":"aut","family":"Mayer","given":"Jiri"},{"family":"Hallek","given":"Michael","display":"Hallek, Michael","role":"aut"},{"given":"Kirsten","family":"Fischer","role":"aut","display":"Fischer, Kirsten"}],"language":["eng"],"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"12 Jun 2013"}],"note":["Gesehen am 27.05.2021"],"name":{"displayForm":["Paula Cramer, Anna-Maria Fink, Raymonde Busch, Barbara Eichhorst, Clemens-Martin Wendtner, Natali Pflug, Petra Langerbeins, Jasmin Bahlo, Valentin Goede, Friederike Schubert, Hartmut Döhner, Stephan Stilgenbauer, Peter Dreger, Michael Kneba, Sebastian Böttcher, Jiri Mayer, Michael Hallek and Kirsten Fischer"]},"recId":"1759085642"} | ||
| SRT | |a CRAMERPAULSECONDLINE1220 | ||